Efficacy of fixed monthly dosing of Lucentis® (Ranibizumab) on subretinal fluid associated with persistent retinal pigment epithelial detachment in neovascular age-related macular degeneration: An exploratory study
Not Applicable
Active, not recruiting
- Conditions
- Diseases of the eye and adnexa
- Registration Number
- KCT0002804
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
1. age older than 50 years 2. known choroidal neovascularization secondary to age related macular degeneration as demonstrated by fluorescein angiography 3. persistent pigment epithelial defect (with possible serous component) and subretinal fluid due to choroidal neovascularization
Exclusion Criteria
1. history of previous vitrectomy 2. prior photodynamic treatment and/or photocoagulation on macular region 3. patients had other retinal conditions other than typical AMD 4. previous history of systemic of ocular corticosteroid medication 5. active intraocular inflammation or systemic infection.
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in volume and maxium heigh of subretinal fluide and pigment epithelial defect;Changes of visula acuity and central macular thickness
- Secondary Outcome Measures
Name Time Method Analysis of factors affecting therapeutic response